Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant either must have ceased lactating at screening; or if still lactating or actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to their infant(s).~* Participant had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).~* Participant had a HAM-D total score of ≥20 and ≤25 at screening and Day 1 (prior to dosing).~* Participant was ≤ six months postpartum.~* Participant was amenable to intravenous therapy.~Key Exclusion Criteria:~* Active psychosis.~* Attempted suicide associated with index case of postpartum depression.~* Medical history of bipolar disorder.~Note: Other protocol-defined inclusion/exclusion criteria applied.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received an infusion rate equivalent to the 90 micrograms per kilogram per hour (μg/kg/h) group.
- SAGE-547 90 μg/kg/h (Type: EXPERIMENTAL): Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).